Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.
Stephen Schuster, MD, discussed how they are prioritizing patients with more aggressive lymphomas, with emphasis on tumor volume and serum LDH levels during the COVID-19 pandemic.
A recent study found 32 new sites on the human genome where variations in a woman’s DNA could alter her risk level, both increase and decrease, of getting breast cancer.
Researchers found that patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy.
Patients with pretreated microsatellite instability-high cancers treated with immune checkpoint inhibitors were found to have high activity, independent of tumor type and drug used.
This study suggested that Medicaid expansion could have survival benefits for men with non-small cell lung cancer, however the same association pattern was not observed for women.
The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.
A workshop group assessed the use of multidimensional data obtained from patients with cancer and the computational methods used to analyze the data.
Recommendations for patients who develop COVID-19 while receiving immunotherapy or other advanced immune-engaging therapies.